Delcath Systems, Inc. Q1 FY2026 earnings call

Key operational highlights include site activation with an average pace of ~1.1 - 1.2 per month, with expectation of ~37 sites; Chopin data well - received by new and existing sites, majority of new sites planning Chopin - like protocol; ESMO breast cancer data shows heavily pretreated patients with manageable adverse events and reasonable survival in advanced breast cancer context; Sales territories adjusted by slicing existing territories for concentrated effort; Europe important for data generation.

Not explicitly detailed in terms of absolute financial performance and revenue contribution% for product segments

Management expects same seasonal impact as last year for remaining quarters, has implemented incentives for sales force to increase backup treatment teams to offset some seasonality, but seasonality due to patient postponement of treatment is hard to impact.

Risks include seasonal impact like training team vacation reducing center capacity and patient treatment postponement, difficulty in measuring referrals due to HIPAA compliance, and reimbursement issues in Europe.

Q: Regarding the goal of 40 sites by Q1 2027, how much relying on new sales territories and funnel?

A: Territories are not new geographies, just slicing existing ones for concentrated effort; Q: On guidance, assumptions for remaining three quarters revenue?

A: Assume same seasonal impact as last year, working on addressing capacity via sales force incentives but patient postponement hard to impact; Q: About breast cancer data median cycles?

A: Clinical protocol calls for two, current median one reflects real - world practice with heavily pretreated patients; Q: About referral measurement?

A: Grappling with accurate metric due to HIPAA compliance; Q: About Chopin publication and European adoption?

A: European growth hampered by reimbursement, modest single - digit growth expected, Europe important for data generation; Q: About NCRC trial enrollment?

A: 13 sites opened, 7 patients enrolled, momentum picking up, expect enrollment to pick up in this year and next year with interim results by end of 2027.